Acucela Inc. is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Acucela’s development pipeline include drug candidates and therapeutics for the treatment of retinitis pigmentosa, proliferative diabetic retinopathy, diabetic macular edema, AMD, Stargardt disease, cataract and presbyopia. The company is also developing a monitoring device for neovascular retinal diseases, to be used directly by patients. http://www.acucela.com; http://www.kubotaholdings.co.jp/en/
Looking for a particular Acucela Inc. employee's phone or email?
The Acucela Inc. annual revenue was $26.1 million in 2026.
Roger Girard is the CEO and President and Chairman of Acucela Inc..
14 people are employed at Acucela Inc..
Acucela Inc. is based in Seattle, Washington.
The NAICS codes for Acucela Inc. are [3254, 325, 32541, 32].
The SIC codes for Acucela Inc. are [283, 28].